These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23955246)

  • 21. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
    Javanbakht M; Moradi-Lakeh M; Yaghoubi M; Esteghamati A; Mansour Ghanaie R; Mahmoudi S; Shamshiri AR; Zahraei SM; Baxter L; Shakerian S; Chaudhri I; Fleming JA; Munier A; Baradaran HR
    Vaccine; 2015 May; 33 Suppl 1():A192-200. PubMed ID: 25919160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
    Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
    Okafor CE; Ekwunife OI
    Lancet Glob Health; 2021 Aug; 9(8):e1088-e1100. PubMed ID: 34297961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Socioeconomic Impact of the Rotavirus Vaccine in Korea: Comparing the Epidemiologic and Economic Characteristics of Rotavirus Gastroenteritis Before and After the Introduction of Vaccines.
    Cho H; Lee H; Kim DS; Kim HM; Kim JH; Kim AY; Kang HY
    Pediatr Infect Dis J; 2020 May; 39(5):460-465. PubMed ID: 31990891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
    Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
    Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
    Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
    Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted.
    Thomas SL; Walker JL; Fenty J; Atkins KE; Elliot AJ; Hughes HE; Stowe J; Ladhani S; Andrews NJ
    Vaccine; 2017 Jan; 35(4):680-686. PubMed ID: 28007397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rotavirus vaccines: development, current issues and future prospects.
    Cunliffe NA; Bresee JS; Hart CA
    J Infect; 2002 Jul; 45(1):1-9. PubMed ID: 12217724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rotavirus vaccines: targeting the developing world.
    Glass RI; Bresee JS; Turcios R; Fischer TK; Parashar UD; Steele AD
    J Infect Dis; 2005 Sep; 192 Suppl 1():S160-6. PubMed ID: 16088799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.
    Aliabadi N; Tate JE; Parashar UD
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5(Suppl 5):S128-S135. PubMed ID: 27129416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Kallen L; Atherly D
    Lancet Glob Health; 2019 Dec; 7(12):e1664-e1674. PubMed ID: 31708147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
    Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
    Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.
    Plosker GL
    Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.
    Carvalho N; Jit M; Cox S; Yoong J; Hutubessy RCW
    Pharmacoeconomics; 2018 Jan; 36(1):79-90. PubMed ID: 28905279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan.
    Anwari P; Debellut F; Pecenka C; Parwiz SM; Clark A; Groman D; Safi N
    Vaccine; 2018 Dec; 36(51):7769-7774. PubMed ID: 29107346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.